FAQ: Preparing for Limb Lengthening Surgery

Baseline strength, flexibility, transfers, and assistive-device practice can make postoperative tasks easier, but limb-lengthening-specific randomized evidence is limited. A therapist who knows the proposed segment and restrictions should record baseline measures and teach only exercises approved by the surgical team.

Routine Doppler screening is not required for every patient. The team should perform a structured blood-clot risk assessment and order ultrasound or other testing when symptoms, prior clots, family history, vascular findings, medication, immobility, or another risk factor makes it appropriate. [1]

There is no safe universal stop list or one-to-two-week rule. Some products can affect bleeding, blood pressure, sedation, anesthesia, or withdrawal. Provide the exact product, dose, and last-use date, including nonprescription drugs and herbal products, and obtain a written medication plan from the surgeon and anesthesiologist.

Testing is chosen from the history, examination, anesthesia plan, age and comorbidities, indication, device, and facility policy. Full-length standing radiographs are common for length and alignment. CT, MRI, DEXA, vascular studies, cardiac testing, and specialized laboratory tests are risk- or question-based rather than universal.

There is no evidence-based universal BMI, calorie target, or supplement bundle for all methods. Nutritional risk, weight stability, smoking or nicotine exposure, vitamin or mineral deficiency, and medical conditions should be assessed individually. Correct a documented deficiency under clinical guidance rather than self-prescribing high doses.

Do not stop an antidepressant abruptly unless the prescribing and perioperative teams direct it. Continuation or adjustment depends on the exact drug, withdrawal risk, bleeding and interaction concerns, anesthesia, and mental-health stability. The prescriber, surgeon, anesthesiologist, and pharmacist may need a coordinated plan.

Disclose every oral, topical, injected, and implanted treatment. Whether it is continued depends on cardiovascular effects, clotting risk, interactions, withdrawal, and the reason for treatment. A category-level FAQ cannot safely decide for an individual drug and patient.

Botulinum toxin A has been studied as an adjunct in lower-limb lengthening and deformity correction, but it is not a universal standard and protocols vary. Potential muscle-relaxing effects must be weighed against weakness, dose, timing, anatomy, and the rehabilitation plan by the treating team. [2]

Arrange accessible housing, caregiver support, mobility equipment, local emergency care, therapy, transport, medication legality and supply, records, insurance or self-pay contingency, and a written plan for delayed travel or revision. Confirm these before making nonrefundable bookings.